Foreign media focus on the reevaluation of China's medical AI! “Forbes” In-depth Analysis of Deshi Technology (02526.HK): iMED-6.0 takes the top and runner-up in the international double list, rivaling the US stock Tempus AI

On November 13, the authoritative international financial media “Forbes” (Forbes) recently published an in-depth article entitled “How China's Medical AI Can Win Back the Market”, listing the Hong Kong stock listed company DIAGENS (02526.HK) as the core litmus test for revaluing China's medical AI, and closely benchmarking it with Tempus AI, the leading medical AI company that surged 90% in the US this year. According to the report, Deshi Technology officially released iMediimage 6.0 (including medium specification Thoth and small specification Aegis), a sixth-generation large-scale general medical imaging model with a completely restructured underlying architecture, to the world on November 12. Among the two most authoritative international evaluation benchmarks MMMU (Health and Medicine) and MedBench VLM, iMED-6.0 both took 1st and 2nd place in the world, surpassing GPT-4V, GPT-5.5, Gemini-3.5-Flash, Claude Opus 4.7 and mainstream domestic general models; its Aegis model also achieved a clinical breakthrough in “one chest and abdominal CT scan, covering 8 major anatomical regions and accurately detecting 509 diseases and imaging symptoms.” The series was published on overseas X platforms, and the number of reads of a single post in less than 24 hours has already exceeded 853,000. “Forbes” emphasizes that Deshi Technology is building a “Microsoft Office for the medical AI industry” through the zero-code platform iMedloop. In the first half of this year, the company's MaaS (model as a service) revenue doubled year-on-year to 94.5 million yuan, accounting for 87% of total revenue. Within half a year, it has collaborated with 99 hospitals to build 158 specialist diagnostic models. With the implementation of China's NMPA Class III certification, EU CE approval, and US FDA Class II review progress (expected to be approved in 2027 Q1), Deshi Technology, which has both a very small circulation market and high platform-based growth, is becoming the focus of global capital revaluation of China's hard technology healthcare. (Huatai Securities previously gave it a “buy” rating for the first time, with a target price of HK$296.13.)